These data thus lend support to CDK 4/6 inhibitors and ET combination treatment as first-line and subsequent-line treatment in patients with HR+, HER2- advanced breast cancer, without the limitation of patients’ or disease characteristics. Here, ERBB2 is linked to breast carcinoma.